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In inflamed tissues, neutrophils are exposed to a variety of stimulatory mole-
cules of different origin that condition their microbicidal and tissue-damaging
activities. The best known stimuli are FMLP related to bacterial products (1),
C5a formed upon complement activation (2), and two bioactive lipids, platelet-
activating factor (PAF)' and leukotriene B4 (LTB4) (3-5). Products like PAF and
LTB4, which are released by stimulated phagocytes and have themselves stimu-
latory properties, may act as enhancers of antimicrobial defense and inflamma-
tion (6, 7). Of particular interest are products of activated mononuclear phago-
cytes, which are likely to influence neutrophil function at sites of chronic
inflammation. We have cultured human blood mononuclear cells in the pres-
ence of LPS and different lectins and have tested the conditioned media for the
presence of factors acting on the neutrophils. In this paper we describe a neu-
trophil-activating factor (NAF) produced by stimulated monocytes that induces
exocytosis and the respiratory burst. The effects of NAF on human neutrophils
are similar to those of FMLP and C5a, but appear mediated by a novel and
selective surface rceptor.
The results presented here were obtained over the current year using a par-
tially purified preparation of NAF. Only upon completion of the present study
did we succeed in purifying NAF to homogeneity. The identification of 32 of 50
presumed residues by amino acid sequencing showed that NAF is a novel poly-
peptide (8). Pure NAF has an ^-80-fold higher specific activity than the partially
purified preparation. Both preparations, however, were qualitatively similar;
they induced exocytosis and a rapid and transient respiratory burst response in
human neutrophils, and showed complete cross-desensitization upon repeated
application to the cells.
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Materials and Methods
Materials.
￿
LPS (from Escherichia coli 055 :B5) was obtained from Difco Laboratories
Inc., Detroit, MI; BSA from Fluka AG, Buchs, Switzerland; Ficoll-Paque from Pharmacia
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AG, Uppsala, Sweden; heparin, cytochrome c (type III from horse heart), trypsin (type
III), and horseradish peroxidase from Sigma Chemical Co., St. Louis, MO; neomycin,
cytochalasin B, and luminol, from Serva GmbH, Heidelberg, Federal Republic of Ger-
many; sodium azide and polyethylene glycol 6000 from Merck AG, Darmstadt, FRG; chy-
motrypsin (Enzygel) and proteinase K from Boehringer GmbH, Mannheim, FRG; FMLP,
1-0-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF) from Bachem AG, Buben-
dorf, Switzerland; and Quin-2/AM from Calbiochem AG, Luzern, Switzerland. The elas-
tase substrate N-succinyl-L-alanyl-L-alanyl-L-prolyl-L-valine-7-amido-4-methylcoumarin
was provided by Dr. T. G. Payne, Preclinical Research, Sandoz Ltd., Basel, Switzerland.
Human C5a was a gift of Dr. C. A. Dahinden, Department of Clinical Immunology, Uni-
versity of Bern, Bern, Switzerland.
Media and Solutions.
￿
Two culture media were used, MEM and MEM-PPL. MEM con-
sisted of Eagle's MEM from Seromed GmbH, Munich, FRG, supplemented with 25 kg/
ml neomycin and buffered to pH 7.4 with 25 mM NaHC03 and 20 mM Hepes. MEM-
PPL contained, in addition, 1% pasteurized plasma protein solution (5% PPL SRK, Swiss
Red Cross Laboratory, Bern, Switzerland) and 100 IU/ml penicillin/streptomycin (Gibco
AG, Basel, Switzerland). Two PBS solutions (pH 7.4) were used: (a) PBS, a Cal+- and
Mg2'-free solution consisting of 137 mM NaCl, 2.7 mM KCI, 8.1 mM Na2HP04, and 1 .5
mM KH2PO4, and (b) PBS-BSA containing, in addition to the above, 0.9 mM CaC12, 0.49
MM MgC12, and 2.5 mg/ml BSA. Stock solutions were used for LPS (10 mg/ml in PBS),
heparin (1,000 IU/ml in distilled water), FMLP (10 mM in DMSO), PAY (10 mM in PBS-
BSA), and cytochalasin B (5 mg/ml in DMSO). The final DMSO concentration never
exceeded 0.2%.
Cell Preparation.
￿
Citrated donor blood stored for up to 20 h at 4-10°C (Swiss Red
Cross Laboratory) was used. Single buffy coats diluted fourfold with PBS supplemented
with 13 IU/ml of heparin were layered on a Ficoll-Paque gradient for separation of neu-
trophils and mononuclear cells (9). The mononuclear cells were washed three times with
MEM and resuspended at 5 X 106 cells/ml in MEM-PPL for culturing or in MEM for
elutriation. Monocytes and lymphocytes were separated in a JE6 elutriation rotor oper-
ated by a J6-M refrigerated centrifuge (Beckman Instruments, Inc., Palo Alto, CA) as
previously described (10). The elutriation medium consisted of PBS supplemented with
0 .01% EDTA, pH 7.4, and 1 % BSA. The flow rate was kept constant at 18 ml/min, the
temperature was 10°C and the rotor speed was reduced stepwise from 3,130 to 2,100
rpm. Cells were collected in two 45-ml fractions each at five speeds, 2,930 and 2,790
rpm for lymphocytes and 2,430, 2,330, and 2,230 rpm for monocytes. They were washed
once in MEM-PPL (250 g for 10 min), checked by differential counting, and the purest
preparations (100% lymphocytes and 95% monocytes, respectively) were used for culture
experiments. Neutrophils were isolated from the pellet following Ficoll-Paque centrifu-
gation as described by Weening et al. (11) and were finally suspended (10" cells/ml) in
isotonic NaCl containing 0.05 mM CaCl2 and kept at 10°C until use . These preparations
consisted of 95-98% granulocytes.
Cell Cultures. Mononuclear cells or purified lymphocytes and monocytes were cul-
tured for different periods in MEM-PPL. The cells (5 X 106/ml unless stated otherwise)
were seeded in 1 ml of medium into 24-well culture plates (Nunc-InterMed, Roskilde,
Denmark). Adherent cells were obtained from the mononuclear cell fraction (5 X 10"
cells per well) by incubation for 1 h at 37°C followed by removal of the medium and
rinsing twice. Large scale cultures of mononuclear cells (1 .2-1 .5 1, containing 5 X 106
cells/ml MEM-PPL) were prepared in 2-liter glass culture bottles (Schott Glaswerke,
Mainz, FRG) equipped with a stirring device.
Partial Purification of NAF
￿
Mononuclear cells were cultured for 48 h in MEM-PPL
supplemented with 100 ng/ml of LPS in stirred culture bottles. The culture supernatant
was then collected, centrifuged at 20,000 rpm for 20 min at 4°C to remove particulate
material, and loaded onto a 10-ml phosphocellulose column (Whatman P11, 1 .4 X 6
cm) equilibrated with 20 mM potassium phosphate buffer, pH 7.2, containing 20 mM
NaCl and 5% glycerol. The column was washed with 30 ml of the above buffer and was
then eluted with 90 ml of a linear NaCl concentration gradient (0.02-1 .5 M) in the samePEVERI ET AL.
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buffer. Fractions of 2 ml were collected in 0 .1% polyethylene glycol and tested for NAY
and IL-1 activity. Absorbance at 280 nm was monitored continuously as a measure for
protein (Uvicord SII; LKB Instruments, Bromma, Sweden) . Fractions with the highest
NAF activity were dialyzed overnight at 4°C against PBS using a membrane with a molec-
ular weight cut-off of 1,000 (Spectrapor; Spectrum Medical Industries Ltd., Los Angeles,
CA) .
NAF Assay.
￿
A microtiter plate assay for elastase release from human neutrophils (12)
was used with minor modifications. Briefly, 100-AI portions of a neutrophil suspension
(107 cells/ml) treated for 10 min with 5 jug/ml of cytochalasin B were dispensed into the
wells containing 125 nmol of the elastase substrate and the test sample in 150 Al PBS-
BSA. For each plate, a background and a stimulation control were included in which the
test sample was replaced with PBS-BSA or PAF in PBS-BSA (final concentration 0.1 and
1 .0 AM, respectively). The assay was performed at room temperature using a Titertek
Fluoroscan (Elflab, Helsinki, Finland).
IL-1 Assay.
￿
IL-1 activity was measured by the thymocyte proliferation assay according
to Rosenwasser and Dinarello (13) .
Resistance to Proteolysis and Denaturation.
￿
Samples of partially purified NAF were sub-
jected to the following treatments: (a) incubation at 37°C with and without trypsin, chy-
motrypsin, or proteinase K (100 kg/ml), followed by the addition of an excess of BSA (2
mg/ml) to stop NAF proteolysis; (b) heating at 56, 80, or 95°C (as compared with 22°C
for control); (c) exposure to pH 2 or 10 (at 22°C) followed by adjustment to pH 7.4 (as
compared with pH 7.4 for control); (d) exposure to 2 M lithium chloride, 6 M guanidi-
nium chloride, 1% 2-ME or 0.5% SDS for 3 h at 22°C, followed by dialysis for 24 h at
4°C against PBS. When additions were made, samples without NAF were handled in the
same way and were tested for possible influence on the NAF assay.
Exocytosis.
￿
Neutrophils (5 X 106/ml) suspended in PBS-BSA were preincubated with
or without cytochalasin B (5 Ag/ml) at 37°C for 5 min. Exocytosis was then initiated by
adding the appropriate stimulus and was stopped 15 min later by rapid cooling in ice
followed by centrifugation. Vitamin B, 2-binding protein, 0-glucuronidase, and LDH
were determined in the cell-free media and cell pellets, and marker release was expressed
in percent of the total cellular content (14).
Superoxide Formation.
￿
Superoxide formation was measured at 37°C as the SOD sen-
sitive reduction of ferricytochrome c (15). The assay mixture (1 ml) consisted of 3 X 106
cells/ml PBS-BSA containing 85 AM cytochrome c. Absorbance changes were recorded
in a Hewlett-Packard Co. (Palo Alto, CA) 8451A diode array spectrophotometer
equipped with a thermostated seven-place cuvette exchanger.
H202 Formation.
￿
H202 formation was determined by chemiluminescence as described
by Wymann et al. (16) . The assay mixture containing 0.1 mM sodium azide, 0.01 mM
luminol, 9 U/ml horseradish peroxidase, and 106 neutrophils in 1 ml of PBS-BSA was
preincubated for 10 min at 37°C and the reaction was started by stimulus addition.
Cytosolicfree Ca" Measurements.
￿
Neutrophils were loaded with quin-2 by incubating
0 .2 nmol quin-2/AM per 106 cells for 15 min at 37°C. After centrifugation, the loaded
cells were resuspended in a buffered saline medium containing 1 mM CaC12 (17).
Changes in the cytosolic free calcium concentration ([Ca2+];) were calculated from the
fluorescence of the cell suspensions as described by von Tscharner et al. (17).
Results
NAF Assay.
￿
The stimulus-dependent release of elastase by cytochalasin B-
treated human neutrophils was adopted as an assay for NAF activity. In Fig. 1
the dependence of elastase release on the amount of NAF-containing condi-
tioned medium is shown. A linear relation was obtained when the amount of
NAF was plotted on a logarithmic scale.
NAF Production.
￿
Mononuclear cell cultures (5 X 106 cells/ml) consisting of
monocytes and lymphocytes in a ratio of - 1 :5 produced NAF when stimulated1550
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with LPS (100 ng/ml), Con A (10 Ag/ml), or PHA (5 jug/ml). NAF accumulated
in the medium over 24 h and the production leveled off between 24 and 48 h.
No NAF was formed in the absence of a stimulus. Being most potent, LPS was
used in all subsequent experiments. Fig. 2 shows the time course of NAF pro-
duction and dependence on the concentration of LPS that was already effective
between 0.1 and 1 ng per 5 X 106 mononuclear cells. The source of NAF was
studied using different mononuclear cell preparations. Fig. 3 a shows the LPS-
dependent generation of NAF by the total mononuclear cell fraction and the
'c
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FIGURE 1 . NAF induced elastase release by cytochalasin B-
treated human neutrophils. Dependence on the amount of
NAF-containing conditioned medium added. Conditions: 5 X
10' mononuclear cells were cultured for 24 h in 1 ml of
medium containing 100 ng LPS. Inset, NAF plotted on a log
scale.
FIGURE 2. NAF production induced by LPS.
Mononuclear cells were seeded in 24-well culture
plates (5 X 106 cells in 1 ml) and were stimulated
with various concentrations of LPS (0.1 ng to 10 hg/
ml, as indicated). At given times, the media were col-
lected, cleared by centrifugation, and the NAF activ-
ity was determined. Values obtained with cells from
a single donor are shown (means of duplicate cul-
tures). These results are representative for four sim-
ilar experiments performed with cells from different
donors.
FIGUR,: 3. Cellular source of NAF. (a) The total
mononuclear cell fraction (0, 0, 5 X 106 cells/ml) or
cells derived from there by adherence (o, o) were cul-
tured in the presence (0, o) and absence (m, o) of LPS
(100 ng/ml). (b) Monocytes (o, 10' cells/ml) and lym-
phocytes (A, 4 X 106 cells/ml) purified by elutriation
were cultured in the presence of LPS (100 ng/ml).
Media were collected at the indicated times and
tested forNAFactivity. Mean values from five (a)and
six (b) separate experiments, each run in duplicate.
Normalized data are shown, which were obtained by
setting the 24-h value for the total mononuclear cell
fraction (a) or the purified monocytes (b) equal to
1.0. This type of presentation was chosen to account
for (a) the individual variation of NAF production by
cells from different donors and (b) the variable
responsiveness of different neutrophil preparations
used in the NAF assay.monocytes selected from there by adherence. These results confirm that NAF
production is dependent on LPS and indicate that the monocytes are the source
of NAF. The presence of lymphocytes does not appear to influence NAF pro-
duction. Definite proof that NAF is a product of monocytes and not of lympho-
cytes is provided by the experiment shown in Fig. 3 b in which cell populations
purified by elutriation were used. NAF production by mononuclear cell cultures
was sensitive to cycloheximide. Complete inhibition was obtained with 10 wg/ml
cycloheximide added together with LPS (100 ng/ml). Inhibition was only 76 and
30%, respectively, when cycloheximide was added 4 h and 8 h after LPS.
Partial Purification.
￿
The biological properties of NAF were investigated with
a partially purified preparation obtained by phosphocellulose chromatography.
Fig. 4 shows the distribution profiles of protein and two biological activities,
thymocyte proliferation (IL-1) and neutrophil elastase release (NAF), obtained
upon fractionation of the conditioned medium of LPS-stimulated monocytes on
phosphocellulose. The bulk of the protein and most of the IL-1 activity were
recovered in the flow-through volume. Elution with a linear NaCl gradient
yielded the remaining IL-1 activity at low ionic strength followed by a peak of
elastase-releasing activity (corresponding to NAF), which started to elute at 0.5
M and reached its maximum at 0.8 M NaCl . The peak was symmetric and was
preceded by a small shoulder. The distribution of the UV-absorbing material
eluted by the salt gradient did not coincide with the two biological activities
determined. As shown in Fig. 4 and confirmed in 10 similar fractionations, IL-
I and NAF could be resolved completely. There was no elastase-releasing activity
associated with IL-1 and no significant thymocyte proliferation-inducing activity
associated with NAF. The final NAF preparation was obtained by pooling the
fractions with at least 95% of the peak value, and dialyzing overnight against
PBS using a 1,000 mol wt cut-off membrane . Such preparations contained on
average 34 jig/ml protein and 24 X 104 fluorescence units of NAF activity per
milliliter. The units are expressed as the fluorescence increase per 20 min mea-
sured in the 96-well fluorimeter (12) under the conditions described in Materials
and Methods.
Resistance to Denaturation.
￿
Various treatments usually leading to the inacti-
vation of proteins were applied to the NAF preparation. As shown in Table I,
NAF turned out to be remarkably resistant. The activity of the preparation, how-
ever, was destroyed upon prolonged incubation with proteases, indicating that
NAF is a polypeptide. It was therefore interesting to realize that NAF was not
d
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FIGURE 4. Partial purification
of NAF by phosphocellulose
chromatography. The distribu-
tions of protein (absorbance at
280 nm -), NAF (o), and I1-1
(A) are shown.1552
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TABLE I
Physicochemical Properties of NAF
readily inactivated by heat, acid and alkaline pH, and exposure to SDS. Partial
inactivation was obtained with 2-ME, lithium, and guanidinium chloride.
NAF-induced Exocytosis.
￿
The effects of NAF on the release of vitamin B12-
binding protein and 0-glucuronidase, which are constituents of the specific and
the azurophil granules, respectively, are summarized in Table 11 . NAF induced
exocytosis of specific granules only, unless neutrophils pretreated with cyto-
chalasin B were used, in which case release from both types of granules was
obtained. Under the latter conditions, the release of 0-glucuronidase was par-
alleled by that of elastase, the marker used to test for NAF activity (Fig. 1) . In
quantitative terms, the exocytosis-inducing properties of NAF were similar to
TABLE II
Stimulus-dependent Exocytosis by Human Neutrophils
Mean values ± SD. CB, cytochalasin B, 5 jug/ml.
Percent release of
Stimulus CB Vitamin B, r-
binding
protein
R-Glucuronidase Lactate
clehydrogenase Number of'
experiments
None - 6.0±0.4 2.1 ±0.4 6.2±2.5 3
NAF 50 Al - 12.9±1 .6 2.7±1 .3 5.8±0.7 4
100u1 - 13.9±2 .1 3.0± 1 .3 6.8±2.2 4
FMLP 0.1 AM - 14.0+0.9 2.3±0.8 5.7± 1 .1 3
None + 10.0± 1 .1 2.4±0.2 7.0±3.2 3
NAF 50 Al + 25.6 ± 3.4 7.9 ± 2.0 6.7 ± 1 .6 6
NAF 100 Al + 26.8 ± 4.9 8.5 ± 1 .7 7.3 ± 2.1 4
FMLP 0 .1 AM + 35.6±5.5 12.1 ±4.4 5.3± 1 .6 3
Treatment Conditions Relative
activity
Temperature 22°C, 3 h 100
56°C, l h 82
80°C 15 min 80
95°C,5 min 66
pH 2.0 22°C, 3 h 76
pH 10.0 22°C, 3 h 90
SIDS (0.5%) 22°C, 3 h 100
2-ME (1 .0%) 22°C, 3 h 30
Lithium chloride (2 M) 22°C, 3 h 52
Guanidinium chloride (6 M) 22°C, 3 h 68
Trypsin (100 jug/ml) 37°C, 4 h 100
37°C, 12 h 8
a-Chymotrypsin (100 ug/ml) 37°C, 4 h 80
37°C, 12 h 1
Proteinase K (100 ug/ml) 37°C, 12 h 0those of the chemotactic peptide FMLP. Neither stimulus increased the release
of the cytosolic enzyme lactate dehydrogenase above control levels, indicating
that cell damage was negligible .
NAF-induced Respiratory Burst.
￿
The results presented in Table III show that
NAF elicits the respiratory burst in human neutrophils. A gradual increase in
the rate of superoxide generation was obtained upon stimulation with increasing
amounts of NAF. Recordings of the time course of H202-dependent chemilu-
minescence were used to compare the fine structure of the respiratory burst
induced by NAF, FMLP, and C5a. As illustrated in Fig. 5, all three peptides
elicited rapid and transient responses of similar shape and duration. The time
between stimulus addition and onset of H202 production was ^- 2 s in all cases,
a value previously determined upon stimulation with FMLP, C5a, PAF, and leu-
kotriene B4 (18).
It has recently been shown (6, 7, 19) that pretreatment with PAF enhances
the respiratory burst response of human neutrophils to a subsequent challenge
with FMLP or C5a. As shown in Fig. 6, the same phenomenon was observed
with NAF. In PAF-pretreated cells, NAF-dependent superoxide production was
markedly enhanced over controls.
Evidence for an NAFReceptor on Human Neutrophils.
￿
The remarkable similarity
of the effects of NAF, FMLP, and C5a suggested that NAF, like the chemotactic
peptides, must act through a surface receptor. This suggestion was substantiated
by the demonstration of a NAF-dependent enhancement of cytosolic free Ca"
([Ca2+]i) and of a desensitization of the neutrophils upon repeated stimulation
30 sec
TABLE III
NAF-dependent Superoxide Production 6y Human Neutrophils
Mean values ± SD
PEVERI ET AL.
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FIGURE 5. Respiratory burst response.
H202-dependent chemiluminescence after
stimulation with partially purified NAFand
approximately equally active concentra-
tions of C5a or FMLP.
NAF Cytochrome c reduction Number of
experiments
Al nmol/min/10fi cells
10 1.45 ± 0.63 5
20 2.32 ± 0.56 8
30 2.51 ± 0.50 3
50 3.51 ± 0.69 8
100 3.69 21554
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with NAF. As shown in Fig. 7, NAF induced a rapid, transient increase in
[Ca21] ;, characteristic of receptor agonists and similar to that induced by FMLP.
The effects of repeated stimulation with different combinations of NAF,
FMLP, and C5a are shown in Fig. 8. When the neutrophils were first stimulated
with NAF or C5a and then with FMLP, two independent respiratory burst
responses were obtained (Fig. 8a). Superoxide production induced by FMLP was
identical with or without prestimulation, showing that cells that had responded
to either NAF or C5a remained fully sensitive to a structurally unrelated second
stimulus . As shown in Fig. 8 b, analogous results were obtained when the neu-
trophils were first stimulated with NAF and then with C5a or vice versa. How-
ever, when the same stimulus was applied twice, no second response was
obtained. Thus, complete densensitization to both NAF and C5a, but no cross-
desensitization, could be demonstrated. Similarly, no cross-desensitization was
observed in analogous experiments with combinations of NAF and PAF (see also
Fig. 6) or NAF and LTB4 (data not shown) . Taken together, these results
strongly suggest that NAF acts via a receptor, and provide evidence that the
NAF receptor is unrelated to those of the already known agonists.
Effect ofSerum.
￿
In serum or plasma, C5a is rapidly converted to its virtually
inactive des-Arg derivative by a carboxypeptidase (20). In view of the functional
similarities between NAF and C5a, their susceptibility to serum was compared.
As shown in Fig. 9, a serum treatment that completely inactivated C5a did not
affect NAF activity.
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FIGURE 7. NAF-induced change in cyto-
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fluorescence
curves of neutrophils stimulated with NAF
(1 or 5 yl of the partially purified prepa-
ration) or FMLP (0.1 yM).
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FIGURE 6. Enhancement of
NAF-induced respiratory
burst by PAF pretreatment.
Neutrophils were preincu-
bated for 2 min either in the
absence (left) or presence
(right) of 0 .1 WM PAF and
were then stimulated with 10
or 50 juI of partially purified
NAF as indicated. As re-
ported previously (7), PAF
had no detectable O2--induc-
ing activity under these con-
ditions. Recordings of cyto-
chrome c reduction are
shown. Arrowheads indicate
NAF addition.a
11
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FIGURE 8.
￿
Superoxide production in response to sequential stimulation with partially pur-
ified NAF, C5a, and FMLP. (a) Neutrophils were first stimulated with NAF or C5a and then
with FMLP. (b) Neutrophils were first stimulated with NAF or C5a and then either with the
same or the alternate stimulus as indicated. Recordings of cytochrome c reduction are shown.
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FIGURE 9.
￿
Effect of serum on NAF and C5a. Approx-
imately equally active samples of partially purified NAF
and C5awere incubated for5 min at 37°C with or with-
out fresh human serum, and were then added to the
neutrophils to induce the respiratory burst (arrowheads).
(a) C5a in PBS-BSA; (b) C5a in serum; (c) serum alone;
A NAF in PBS-BSA; (e) NAF in serum. Recordings of
cytochrome c reduction are shown.
Discussion
This paper shows that cultured human blood monocytes stimulated with LPS,
PHA, or Con A produce and release a neutrophil-activating factor, which we
tentatively termed NAF. The time course of NAF production and the inhibition
by cycloheximide indicate that de novo protein synthesis is required. Lympho-
cytes did not produce NAF, and there was no indication of their involvement as
enhancers or inhibitors of production since the yield was proportional to the
number of monocytes present and independent of lymphocyte additions.1556
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A Novel Neutrophil Receptor Agonist.
￿
The goal of the present study was to
characterize some of the biological effects of NAF on its target cell, the human
neutrophil, and to compare it with well established neutrophil-activating agents.
NAF elicited the two major neutrophil responses, the respiratory burst and
granule release. Four lines of evidence indicate that NAF acts on a selective
surface receptor and activates the neutrophils via a signal-transducing process
similar to the one initiated by chemotactic peptides. (a) Like other receptor ago-
nists, i.e. FMLP, C5a, PAF, and LTB4, NAF induced a rapid, transient increase
in [Ca"] ; ;(b) real-time recordings of superoxide and H2O2 production showed
that the respiratory burst elicited by NAF was similar in onset and time course
to that induced by FMLP or C5a; (c) repeated stimulation with NAF showed full
desensitization of the neutrophils, a phenomenon that was also shown to occur
with both FMLP and C5a (21). No cross-desensitization, however, was observed
upon sequential stimulation with NAF and FMLP or NAF and C5a; (d) the respi-
ratory burst response to NAF was potentiated by pretreatment of the cells with
PAF, as previously reported for the response to FMLP and C5a (6, 7, 19), sug-
gesting a similarity in signal transduction .
NAF-like Factors.
￿
It was reported some years ago that alveolar macrophages
release factors that are chemotactic for neutrophils (22-24), and that may thus
condition the infiltration of pulmonary tissues by inflammatory cells (23). Other
investigators showed subsequently that alveolar macrophage products enhanced
the microbicidal activity of neutrophils, and suggested that such a process may
be important in the defense of lung tissue against infection (25, 26). Purification
by gel filtration and chromatofocusing led to the identification of a protease-
sensitive factor termed NAF, with apparent molecular weight of 6,000 and an
isoelectric point of 7.6 (26) . The NAF described in the latter study was reported
to be weakly chemotactic and to enhance oxygen-dependent killing of bacteria
by neutrophils without, however, inducing the respiratory burst by itself. A sim-
ilar mechanism of enhanced host defense was described by Ferrante and
Mocatta (27), who showed that human neutrophils require conditioning with
mononuclear phagocyte culture media to kill Naegleriafowleri. Granulocyte-acti-
vating mediators (GRAM) produced by LPS-stimulated human monocytes were
described more recently by Kapp et al. (28) and Maly et al . (29). Two GRAM
species with apparent mol wt of 60 X 103 and < 104 were reported to elicit a
delayed and long-lasting chemiluminescence response in human neutrophils.
GRAM was sensitive to heat and trypsin and its production was dependent on
LPS stimulation and on de novo protein synthesis. Yet another activating factor,
termed mononuclear cell-derived chemotactn (MOC), apparently a peptide with
a mol wt of 104, that differs from GRAM and C5a was reported by Kownatzki
et al. (30). Most recently Yoshimura et al. (31) described a cationic chemotactic
peptide of ^-104 mol wt, that is released by LPS-stimulated monocytes, and that
is functionally similar to MOC.
Some of the above reports as well as our present data clearly indicate that the
neutrophil-activating peptides released by mononuclear phagocytes are distinct
from the two well-known monokines, IL-1 and tumor necrosis factor (TNF). Sev-
eral of the NAF-like molecules were shown to be considerably smaller than
either monokine (26, 28, 30, 31), and to exert effects that could not be obtainedwith recombinant and highly purified monokines (31). In addition, amino acid
sequencing of purified NAF (8) showed no significant structural homology with
IL-la and ß and TNF-a. In the light of the present evidence, we believe that
early preparations of IL-1, which were shown to induce the respiratory burst
and granule release (32, 33), might have been contaminated with NAF. The
question about similarities among the NAF and the NAF-like factors discussed
remains open due to the lack of sufficient structural information. Despite the
biochemical and functional differences reported, it is conceivable that several of
the NAF-like factors may turn out to be identical.
In view of its functional properties, NAF may be regarded as homologous to
FMLP and C5a. NAF differs, however, in some important aspects from either
chemotactic peptide and is likely to have a distinct role in host defense and
inflammation. Like C5a, NAF is of host origin, but unlike C5a it is generated
by inflammatory cells. Another distinction from C5a is its resistance to degra-
dation by serum and exudate peptidases. NAF, therefore, is expected to persist
and to accumulate in inflamed tissues (as it does in culture) and to have a pro-
longed influence on immigrating neutrophils. While C5a and N-formyl-methio-
nyl peptides are considered to be early mediators of neutrophil activation upon
infection, NAF presumably acts as a second-wave mediator since its generation
depends on the influx of mononuclear phagocytes into the affected tissue.
Mononuclear phagocytes are also major producers of PAF (34), and it is inter-
esting to note that the effect of NAF on neutrophils is enhanced when this lipid
agonist is present. These considerations suggest that NAF may have a particular
role in chronic infection and inflammation. The rapid progress of the structural
characterization (8) will soon lead to the development of analytical methods for
the detection of NAF in inflamed tissues, which shall answer some of the ques-
tions proposed by our present work.
Summary
The biological properties of a neutrophil-activating factor (NAF), which was
recently identified as a novel peptide of 6,000 mol wt (8), are described. NAF
is produced de novo by human blood monocytes upon stimulation with LPS,
PHA, and Con A. It induces two main responses in human neutrophils, i.e.,
exocytosis (release from specific granules in normal, and from specific and azur-
ophil granules in cytochalasin B-treated cells) and the respiratory burst (for-
mation of superoxide and hydrogen peroxide). The action of NAF appears to
be mediated by a surface receptor as shown by the following observations. (a)
NAF induces a rapid and transient rise in cytosolic free Ca"; (b) interaction with
NAF results in desensitization, since the cells do not respond to a second NAF
challenge; and (c) the respiratory burst elicited by NAF is similar in onset, and
time course to that induced by C5a or FMLP. The NAF receptor can be distin-
guished from the receptors of C5a, FMLP; platelet-activating factor, and leu-
kotriene B, by the lack of cross-desensitization. Unlike C5a, the other host-
derived neutrophil-activating peptide, NAF is not inactivated by serum and thus
presumably accumulates in inflamed tissue.
Receivedfor publication 20 November 1987.
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